US$ 22.05
glp-1 obesity drug news updates Weight loss with medicines does not result in a disproportionate loss of muscle mass or function in obese mice and humans: Cell Reports Medicine The next phase of the
Description
Glucagon-like-peptide-1 receptor agonists (GLP-1s) have transformed weight management and treatment of chronic disease

Meisha.

Correspondent Tracy Smith talks with experts who say the drugs might prove useful in treating other diseases associated with obesity (including cancer)

Explore GLP-1 medications like Ozempic and Wegovy

Given the heterogeneity of the included evidencespanning case reports, pharmacovigilance analyses, and observational cohortsthis review is framed primarily as a signal-detection and evidence-mapping exercise rather than a causal-inference analysis
